Age (years) | | 66 (57–74) |
Women, No (%) | | 165 (73) |
Duration of disease (years) | | 8.6 (4.2–17.9) |
Number of months receiving MTX | | 51 (19–97) |
Presence of rheumatoid factors (IgM), No (%) | | 156 (69) |
Administration of low dose corticosteroids, No (%) | | 107 (47) |
Weekly MTX dose (mg) | | 15 (10–17.5) |
Folic acid supplementation, No (%) | | 184 (81) |
Number of tender joints | | 1.0 (0–5.0) |
Number of swollen joints | | 3.0 (1.0–6.0) |
Physician’s global assessment of disease activity (10 cm VAS) | | 2.5 (1.2–4.3) |
Modified Health Assessment Questionnaire | | 0.375 (0–0.750) |
Physician’s assessment of patient’s response to MTX >2 cm (poor response)*, No (%) of patients | | 113 (50) |